India Gleevec purchasing price direct mail website 15811106228 India Gleevec

('h', Before Gleevec was launched, the treatment of gastrointestinal stromal tumors was very difficult. Like other cancers, gastrointestinal stromal tumors are difficult to detect in the early stage. More importantly, traditional radiotherapy and chemotherapy are difficult to treat. There is almost no effect. Patients can only undergo surgical treatment, but surgical treatment cannot completely cure the disease. According to clinical statistics, half of the patients will relapse within two years and require continued surgery. This not only puts huge financial pressure on patients and their families , also brings great pain to the patients themselves. Therefore, preventing recurrence is a problem faced by all patients with gastrointestinal stromal tumors after surgery.
'h', Gastrointestinal stromal tumors are difficult to detect and easy to metastasize< br/> ' h', >Gastrointestinal stromal tumor is the most common malignant tumor of gastrointestinal soft tissue, which is different from common gastric cancer or intestinal cancer. It was previously thought that gastrointestinal stromal tumors can be divided into benign and malignant. However, with the deepening of the understanding of the disease, it has been discovered that there are no truly benign tumors, and even very small gastrointestinal stromal tumors can metastasize.
' h', >The incidence of gastrointestinal stromal tumors is equal in men and women , the peak age of incidence is between 1 and 2 years old. Tumors can occur in any part of the digestive tract, but they are more common in the stomach, followed by the small intestine, esophagus and colorectum. When the tumors are small, they are often asymptomatic and are easily missed or missed. Misdiagnosis. Patients are often discovered accidentally during physical examination, barium meal, gastroscopy or other surgeries, so many patients are already accompanied by metastasis when they are first diagnosed.
' h', >In addition, a considerable number of Patients are discovered due to certain clinical symptoms due to tumor growth. For example, those with tumors located in the esophagus may have difficulty swallowing, those with tumors located in the stomach may have upper abdominal discomfort or upper gastrointestinal bleeding, and those with tumors located in the duodenum are often accompanied by Obstructive jaundice, located in the intestine, may cause abdominal pain, abdominal mass, obstruction, blood in the stool or perforation, etc.
' h', Clinically, surgical treatment of gastrointestinal stromal tumors is mainly performed
' h' ,>Clinical statistics show that approximately %~% of primary gastrointestinal stromal tumors without metastasis can undergo radical surgery. The annual survival rate of patients with gastrointestinal stromal tumors after radical resection is %~%. Patients who cannot be operated on , usually only survive ~ months.
' h', up to
Patients with gastrointestinal stromal tumors will relapse after two years
' h', >Currently clinically due to gastrointestinal stromal tumors The tumors are not sensitive to conventional radiotherapy and chemotherapy, and radical surgery is still the preferred method for primary gastrointestinal stromal tumors.
' h', >However, even after radical surgery, patients still have a high risk of The recurrence rate. After the first surgical resection of the tumor, half of the patients will have recurrence of gastrointestinal stromal tumors in two years, and most recurrent tumors will relapse again after resection.
' h', grid Gleevec was approved for the treatment of gastrointestinal stromal tumor The research results on the recurrence rate of gastrointestinal stromal tumors were published in the world-renowned medical journal "The Lancet".
' h', >Study shows that compared with patients who use placebo, patients who use targeted therapy drugs after surgery can significantly reduce the recurrence rate of gastrointestinal stromal tumors and improve the average survival rate of advanced patients. The time was extended from months to months. At the same time, if targeted drugs are used to suppress tumors before surgery, the success rate of surgery and the postoperative survival rate of patients can also be improved.
' h', >In the same year, both the United States and the European Union approved Gleevec for the treatment of gastrointestinal stromal tumors. China will also approve this effect in 2020, which will give new hope to many patients with gastrointestinal stromal tumors.
'h', Gleevec can prevent the recurrence of gastrointestinal stromal tumors
'h', >Clinical trials have proven that once daily use of 1 mg of Gleevec (imatinib mesylate) targets Among the patients who took the drug, % had no recurrence within one year after surgery, and it could extend the average survival time of advanced-stage patients from months to months, doubling the survival time of patients.
' h', >
For some large gastrointestinal stromal tumors, surgery cannot be carried out rashly, otherwise it is likely to cause tumor rupture and tumor cells to plant and metastasize everywhere in the abdominal cavity. The correct approach should be to first use the targeted drug Gleevec to contain the tumor and then remove it surgically.